If you could vote on Brexit now which option would you choose?

Early approval of a COVID-19 vaccine could stymie the hunt for better ones

Success in the push to find a COVID-19 vaccine at record-breaking speed could hand the world a new problem. The first vaccine to cross the finish line might be only marginally effective, yet it could become the enemy of the good—or even the great—candidates in the wings by disrupting ongoing studies. In all likelihood, the U.S. Food and Drug Administration (FDA) or other regulators will issue the first COVID-19 vaccine approval or emergency use authorization (EUA) for one vaccine while many other candidates have clinical trials still underway or in the planning. At that point, ongoing studies of any vaccine—including that first one—could become unethical because half the participants would get a placebo, at a time a vaccine with established efficacy will be available. “It’s a very vexing issue,” says Christine Grady, who heads the bioethics department at the National Institutes of Health (NIH) Clinical Center, which organized a “grand rounds” webinar on the challenges last week.

Science Magazine - October 15, 2020

View the full story here: https://www.sciencemag.org/news/2020/10/early-approval-covid-19-vaccine-could-stymie-hunt-better-ones